Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. is a health and pharmaceutical company based in Oviedo, Florida, primarily focusing on transdermal and topical technologies for product development. Their lead product, AVERSA technology, works to prevent drug abuse and diversion, especially opioids. Most revenue is generated from consumer transdermal and coated products. Nutriband is progressing towards a 505(b)(2) NDA submission to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025.
The recent private placement of $8.4 million will fund the commercial development of AVERSA Fentanyl for NDA filing. Nutriband is working on the commercial scale-up and pivotal clinical study for FDA approval. AVERSA technology aims to revolutionize opioid patches with abuse-deterrent properties, making them safer and more effective.
By utilizing their proprietary AVERSA™ abuse-deterrent technology, Nutriband is dedicated to preventing drug abuse and misuse while ensuring accessibility to those in need. With a focused approach on innovation and safety, Nutriband is positioned to make a significant impact in the pharmaceutical industry.
Nutriband (NASDAQ: NTRB) has secured a Certificate of Registration from the USPTO for trademark registration Number 7,692,920 on February 18, 2025. The trademark covers product research and development, scientific research and development, biochemical research and development, and pharmaceutical research and development under Class 042.
The Nutriband™ trademark is important for commercializing the company's AVERSA platform technology, designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches. The company's leading product, AVERSA™ Fentanyl, is being developed in partnership with Kindeva Drug Delivery, focusing on scaling up commercial manufacturing before FDA submission. Market analysis by Health Advances projects potential peak annual U.S. sales of $80-200 million for AVERSA™ Fentanyl.
Nutriband Inc. (NASDAQ:NTRB) has formalized an exclusive development partnership with Kindeva Drug Delivery for Aversa™ Fentanyl, an abuse-deterrent fentanyl patch. The partnership involves shared development costs in exchange for milestone payments. The product combines Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch.
The Aversa™ technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The technology is protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China. If successful, Aversa Fentanyl would become the world's first abuse-deterrent opioid patch, with potential peak annual US sales ranging from $80 million to $200 million.
Nutriband Inc. (NASDAQ: NTRB) has announced the appointment of World and European Wrestling Gold medalist and Olympic Silver medalist Anastasia Nichita to its Product Advisory Board. The appointment aims to expand the Nutriband Brand and promote its over-the-counter sports and consumer products internationally.
The company, which develops transdermal pharmaceutical products through its subsidiary Pocono Pharma, produces multiple products including AI Tape. This product combines traditional kinesiology tape benefits with soothing and therapeutic ingredients in a proprietary adhesive mix.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the USPTO for patent application 18/369,241, covering its Aversa™ abuse deterrent technology. This technology is designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches.
The company's lead product, Aversa™ Fentanyl, aims to become the first abuse-deterrent fentanyl transdermal system. The technology utilizes a proprietary aversive agent coating that employs taste aversion to deter oral abuse. The intellectual property is protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China.
According to a market analysis report, Aversa Fentanyl has the potential to achieve peak annual US sales between $80 million to $200 million.
Nutriband (NASDAQ: NTRB) has released its 2024 shareholder letter highlighting significant achievements and 2025 outlook. The company reported record Q3 revenue of $645,796, a 51% year-over-year increase. Key developments include advancing their AVERSA™ Fentanyl product, projected to achieve peak annual U.S. sales of $80-200 million, toward commercialization with partner Kindeva Drug Delivery.
The company secured patent approvals in China and Hong Kong, expanding their intellectual property portfolio to 46 countries. Nutriband raised $8.4 million through a private placement and established an exclusive supplier agreement with Fit For Life Group for major fitness brands. The company plans to submit the New Drug Application (NDA) for AVERSA™ Fentanyl in 2025, with potential regulatory approval expected by year-end.
Nutriband Inc. (NASDAQ:NTRB) has extended its Chinese patent to Macao for its AVERSA™ abuse-deterrent transdermal technology, bringing the total patent coverage to 46 countries and territories. The Macao IP Office assigned patent number J/9010, effective December 17, 2024.
The AVERSA™ technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband is collaborating with Kindeva Drug Delivery to develop AVERSA™ Fentanyl, targeting FDA approval in the first half of 2025. The product has potential peak annual US sales of $80-200 million and aims to be the world's first abuse-deterrent opioid patch.
Nutriband Inc. (NASDAQ:NTRB) reported strong Q3 2024 financial results, with record revenue of $645,796, up 50.94% year-over-year. The company maintains a solid cash position of $5.7 million, with total assets of $12.55 million and stockholders' equity of $11.23 million.
Through its Pocono Pharma subsidiary, Nutriband is expanding its kinesiology tape manufacturing services, with products available in major retailers like Target, Walmart, Walgreens, and CVS. The company continues to progress with AVERSA Fentanyl development, targeting NDA submission in first half of 2025, requiring only a single phase 1 Human Abuse Potential study.
Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.
Nutriband Inc. (Nasdaq: NTRB) has announced its participation in the Noble Conference at Florida Atlantic University in Boca Raton on December 3rd-4th, 2024. Company President and Chairman Serguei Melnik will present on December 4th at 1:30 PM in Conference Room 3, focusing on the company's AVERSA technology.
The company specializes in developing transdermal pharmaceutical products, with their flagship product being an abuse-deterrent fentanyl patch incorporating AVERSA™ technology. This innovative technology can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Presentation details and replay will be available on Channelchek and Youtube after the conference.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Publication for its Hong Kong patent protecting AVERSA™ abuse-deterrent transdermal technology. The patent, assigned Publication Number 40085268 B, will be published on December 20, 2024. AVERSA™ technology is now protected by patents in 46 countries, including major markets. The technology incorporates aversive agents into transdermal patches to prevent abuse of drugs like opioids and stimulants. Nutriband is developing AVERSA™ Fentanyl with Kindeva Drug Delivery, potentially becoming the world's first abuse-deterrent opioid patch with projected annual US sales of $80-200 million.
Nutriband (NASDAQ:NTRB) has received full patent issuance from the Chinese National Intellectual Property Administrant (CNIPA) for its 'Abuse and Misuse Deterrent Transdermal System.' The patent (No: ZL 202211158031) supports the company's AVERSA™ technology, developed by 4p Therapeutics, which incorporates taste aversion to prevent abuse of opioid-based transdermal patches. This follows CNIPA's notice of allowance issued in September 2024.
FAQ
What is the current stock price of Nutriband (NTRBW)?
What is Nutriband Inc.'s primary focus?
What is AVERSA technology?
What is the recent achievement of Nutriband Inc.?
What is Nutriband Inc.'s goal in the pharmaceutical industry?
How is Nutriband Inc. striving for innovation?
